THERAPEUTIC EFFECT OF PAÑCAKARMA IN DYSFERLINOPATHY PRESENTING AS LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2B: A CASE REPORT

Dysferlinopathy is a rare autosomal recessive muscular dystrophy caused by mutations in the dysferlin gene, with a global prevalence of approximately 1–5 cases per million population. Its incidence is estimated to range from 1 in 200,000 to 1 in 1,000,000 live births; however, it is often underdiagnosed due to clinical variability and limited awareness. Clinically, it presents as limb-girdle muscular dystrophy type 2B and is characterized by progressive muscle weakness, difficulty in climbing stairs, calf muscle hypertrophy, elevated serum creatine phosphokinase levels, and a positive Gower’s sign. Currently, there is no definitive cure in conventional medicine, and management remains largely supportive. In Āyurvedic perspective, this may be correlated with Māṁsa-medogata vāta. Pañcakarma therapies play a significant role in improving muscle function in both qualitative and quantitative perspectives. The intervention demonstrated notable improvement in muscle strength, functional mobility, and overall quality of life.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-04-01
DOI
https://doi.org/10.5281/zenodo.19333472
Primary Topic
Muscle Physiology and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

THERAPEUTIC EFFECT OF PAÑCAKARMA IN DYSFERLINOPATHY PRESENTING AS LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2B: A CASE REPORT

Dr. D. Priyadarshini*1, Dr. V. Lakshmana Prasad2, Dr. K. Harshavardhana Appaji3
Zenodo (CERN European Organization for Nuclear Research)
Muscle Physiology and Disorders
article

THERAPEUTIC EFFECT OF PAÑCAKARMA IN DYSFERLINOPATHY PRESENTING AS LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2B: A CASE REPORT

Dr. D. Priyadarshini*1, Dr. V. Lakshmana Prasad2, Dr. K. Harshavardhana Appaji3
article en

Abstract

Dysferlinopathy is a rare autosomal recessive muscular dystrophy caused by mutations in the dysferlin gene, with a global prevalence of approximately 1–5 cases per million population. Its incidence is estimated to range from 1 in 200,000 to 1 in 1,000,000 live births; however, it is often underdiagnosed due to clinical variability and limited awareness. Clinically, it presents as limb-girdle muscular dystrophy type 2B and is characterized by progressive muscle weakness, difficulty in climbing stairs, calf muscle hypertrophy, elevated serum creatine phosphokinase levels, and a positive Gower’s sign. Currently, there is no definitive cure in conventional medicine, and management remains largely supportive. In Āyurvedic perspective, this may be correlated with Māṁsa-medogata vāta. Pañcakarma therapies play a significant role in improving muscle function in both qualitative and quantitative perspectives. The intervention demonstrated notable improvement in muscle strength, functional mobility, and overall quality of life.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 9%
Muscle Physiology and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

THERAPEUTIC EFFECT OF PAÑCAKARMA IN DYSFERLINOPATHY PRESENTING AS LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2B: A CASE REPORT — Dr. D. Priyadarshini*1, Dr. V. Lakshmana Prasad2, Dr. K. Harshavardhana Appaji3 · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS